Skip to main content

Day: December 21, 2022

LifeStance to Present in the 41st Annual J.P. Morgan Healthcare Conference

SCOTTSDALE, Ariz., Dec. 21, 2022 (GLOBE NEWSWIRE) — LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference, which will be hosted in San Francisco, CA. Details of the presentation are as follows:Presenters: Ken Burdick, Chairman and CEO, and Danish Qureshi, President and COODate: Tuesday, January 10, 2023 Time: 7:30 a.m. (Pacific time)Moderated by: Lisa Gill The presentation will be webcast live and will be available on the Events and Presentations section of the LifeStance Health Investor Relations website (https://investor.lifestance.com).   A replay of the webcast will be available after the conclusion of the event and can be accessed on the LifeStance Health...

Continue reading

Brookfield Corporation Announces Results of Conversion of its Series 30 and Series 48 Preferred Shares

BROOKFIELD, NEWS, Dec. 21, 2022 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken into account all election notices received by the deadline for the conversion of its Cumulative Class A Preference Shares, Series 30 (the “Series 30 Shares”) (TSX: BN.PR.Z) into Cumulative Class A Preference Shares, Series 31 (the “Series 31 Shares”) and for the conversion of its Cumulative Class A Preference Shares, Series 48 (the “Series 48 Shares”) (TSX: BN.PF.J) into Cumulative Class A Preference Shares, Series 49 (the “Series 49 Shares”), there were 92,379 Series 30 Shares and 39,620 Series 48 Shares tendered for conversion, which is less than the one million shares required to give effect to conversions into Series 31 Shares and Series 49 Shares, respectively. Accordingly, there will be no...

Continue reading

Patrick Scatuorchio Joins Peapack Capital as Senior Vice President, Business Development Officer

Peapack-Gladstone Financial Corporation Patrick Scatuorchio, Senior Vice President, Business Development Officer at Peapack CapitalBEDMINSTER, NJ, Dec. 21, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Peapack-Gladstone Financial Corporation (NASDAQ Global Select Market: PGC) is proud to announce the appointment of Patrick Scatuorchio as Senior Vice President, Business Development at Peapack Capital, the equipment finance subsidiary of Peapack-Gladstone Bank.  Working out of the organization’s Red Bank, New Jersey location, Mr. Scatuorchio joins Peapack-Capital’s team of experienced equipment finance and leasing professionals. With over 40 years of experience in the equipment finance industry, Mr. Scatuorchio’s knowledge and experience are invaluable to the institution.  He most recently served as Vice President, Territory Manager...

Continue reading

SL Green Realty Corp. to Release Fourth Quarter 2022 Financial Results After Market Close on January 25, 2023

Conference Call to Be Held on January 26, 2023 at 2:00pm ET NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the fourth quarter of 2022 on Wednesday, January 25, 2023 after market close. The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, January 26, 2023 at 2:00 pm ET to discuss the financial results. Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com under “Financial Reports”. The live conference call will be webcast in listen-only mode and a replay will be available in the Investors...

Continue reading

Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During “J.P. Morgan Week 2023”

PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM. All events will be held in-person and are scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2023. Details of the events are as follows: Event: Sachs 6th Annual Neuroscience Forum (Panel)Panel Title: Progress in Alzheimer’s and Cognitive Disorders Date: January 8, 2023Time: 9:30 – 10:25 a.m. PTLocation: Marines Memorial Club, San Francisco, CA Event: Sachs 6th Annual Neuroscience Forum (Corporate Presentation)Date: January 8, 2023Time: 11:20 – 11:40 a.m. PT Location: Marines Memorial Club, San Francisco, CA – Room Regimental Event: Biotech...

Continue reading

Taboola to Participate in Needham Growth Conference

NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) — Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, helping people discover things they may like, today announced that members of its management team will participate in a fireside chat at the Needham Growth Conference on January 11, 2023 at 1:30 p.m. ET. A live webcast and replay of the fireside chat will be available on Taboola’s investor relations website at www.taboola.com/about/investors. About TaboolaTaboola powers recommendations for the open web, helping people discover things they may like. The Company’s platform, powered by artificial intelligence, is used by digital properties, including websites, devices and mobile apps, to drive monetization and user engagement. Taboola has long-term partnerships with some of the top digital properties in...

Continue reading

C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

Eledon to Incorporate the iBox Scoring System in Future Kidney Transplant Trials IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) — Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through the European Medicines Agency’s (EMA) qualification of novel methodologies for drug development. This novel secondary endpoint supports the evaluation of new immunosuppressive therapy (IST) applications for the prevention of kidney transplant rejection and is the first EMA qualified endpoint for any transplant indication. The iBox Scoring System is a composite endpoint of kidney graft function that utilizes multiple clinical, histological...

Continue reading

Singular Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 21, 2022 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California. Singular Genomics’ management is scheduled to present on Thursday, January 12, 2023 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation on the News & Events section of the company’s investor relations website at https://investor.singulargenomics.com/news-events/event-calendar. About Singular Genomics Systems, Inc. Singular Genomics is a life science technology company that develops next-generation...

Continue reading

SpotLite360 Announces Debt Settlement Transaction

DENVER and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) —  SPOTLITE360 IOT SOLUTIONS, INC. (“SpotLite360” or the “Company”) (CSE: LITE) (OTC: SPLTF) (Frankfurt: 87A) announces that its board of directors has approved the settlement of an aggregate $78,375 of debt through the issuance of common shares of the Company (the “Debt Settlement”). Pursuant to the Debt Settlement, the Company issued 653,125 common shares of the Company (the “Shares”) at a deemed price of $0.12 per Share to a creditor of the Company. All securities issued are subject to a statutory hold period which will expire on the date that is four months and one day from the date of issuance. None of the securities issued in connection with Debt Settlement will be registered under the United States Securities Act of 1933, as amended...

Continue reading

Synchronoss Announces More Than 30 Million RCS-Based Messaging Subscribers in Japan

Leveraging the Synchronoss Advanced Messaging Platform, NTT DOCOMO, KDDI, and SoftBank Deliver Cross-Operator Advanced Messaging Service Enabling Users and Brands to Communicate, Interact, and TransactBRIDGEWATER, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (NASDAQ: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced a new milestone in Japan for its Synchronoss Advanced Messaging platform. In collaboration with mobile operators NTT DOCOMO, KDDI, and SoftBank, the Japanese consortium now supports 32.5 million subscribers of +Message, the cross-operator RCS service powered by Synchronoss Advanced Messaging. The current milestone represents a 62 percent increase in subscribers since Synchronoss noted the progress of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.